MapLight's schizophrenia drug fails primary endpoint in Phase 2, sending stock down over 60%

MapLight Therapeutics saw its shares tumble more than 60% after a mid‑stage trial showed that its once‑daily schizophrenia candidate did not meet the primary efficacy endpoint, even though the overall study was deemed a success.

The Phase 2 study evaluated a once‑daily dosing regimen intended to simplify treatment for patients with schizophrenia. While secondary measures showed some promise, the failure to achieve the main goal dampened investor enthusiasm.

Investors had been hoping the new dosing schedule would differentiate the product and accelerate its path to market. The missed primary endpoint is likely to delay further development steps and could affect the company’s financing plans.

Despite the setback, MapLight indicated that the trial’s secondary outcomes remain encouraging, and the company plans to discuss next steps with regulators and its board.

The sharp stock decline reflects the market’s sensitivity to trial readouts in the neuro‑psychiatric space, where any indication of limited efficacy can quickly erode confidence.